Position in EXEL
as of Jun 30, 2026
· filed Aug 7, 2026
Position Value
$310,245
+$157,343 QoQ
Shares Held
5,702
+59.9% QoQ
Ownership
0.002%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#511
of 751 holders
Holding Since
Mar 2025
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Plato Investment Management Ltd holds $8,720,382 across 6 Biotechnology names. EXEL ranks #5 (3.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
6,083 | $3,021,608 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
3,983 | $2,483,559 | |
| 3 | INCY |
Incyte Corp
|
14,856 | $1,684,076 | |
| 4 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
3,671 | $1,105,081 | |
| 5 | EXEL |
Exelixis, Inc.
This page
|
5,702 | $310,245 | |
| 6 | BMRN |
Biomarin Pharmaceutical Inc
|
2,024 | $115,813 |
All Filings in EXEL
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $310,245 | 5,702 | Shares | Sole | 2026-08-07 | |
| 2026-03-31 | $152,902 | 3,565 | Shares | Sole | 2026-05-05 | |
| 2025-12-31 | $412,747 | 9,417 | Shares | Sole | 2026-02-04 | |
| 2025-09-30 | $388,922 | 9,417 | Shares | Sole | 2025-11-05 | |
| 2025-06-30 | $272,149 | 6,174 | Shares | Sole | 2025-08-05 | |
| 2025-03-31 | $214,025 | 5,797 | Shares | Sole | 2025-05-20 | |
| No filing history on record for this holder in this stock. | ||||||